Profiling of the three circulating monocyte subpopulations in human obesity

Journal of Immunology

Volumn 194, Issue 8, 2015, Pages 3917-3923

  Devêvre, Estelle F ^a,b,c,d   Renovato Martins, Mariana ^a,b,c,d   Clément, Karine ^b,c,d,e,f,g   Sautès Fridman, Catherine ^a,c,d   Cremer, Isabelle ^a,c,d   Poitou, Christine ^b,c,d,e,f,g  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b INSERM   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e Institute of Cardiometabolism and Nutrition   (France)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^g Centre de Recherche en Nutrition Humaine Ile de France   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CX3CR1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; SINGLE STRANDED RNA; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 8; AUTACOID; CCR2 PROTEIN, HUMAN; CCR5 PROTEIN, HUMAN; CD14 ANTIGEN; CHEMOKINE RECEPTOR; CX3CR1 PROTEIN, HUMAN; FC RECEPTOR; FCGR3B PROTEIN, HUMAN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; LIPOPOLYSACCHARIDE; TLR4 PROTEIN, HUMAN; TLR8 PROTEIN, HUMAN;

ADULT; ARTICLE; CD14+ CD16+ NONCLASSICAL MONOCYTE; CD142+ CD16+ INTERMEDIATE MONOCYTE; CD142+ CD162 - CLASSICAL MONOCYTE; CELL MIGRATION; CELL SUBPOPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; INFLAMMATION; MALE; MONOCYTE; OBESITY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; AGONISTS; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; IMMUNOLOGY; PATHOLOGY;

ADULT; ANTIGENS, CD14; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GPI-LINKED PROTEINS; HUMANS; INFLAMMATION MEDIATORS; LIPOPOLYSACCHARIDES; MALE; MONOCYTES; OBESITY; RECEPTORS, CCR2; RECEPTORS, CCR5; RECEPTORS, CHEMOKINE; RECEPTORS, IGG; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTOR 8;

EID: 84927592411     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1402655     Document Type: Article

References (41)

1. Cancello, R., and K. Clément. 2006. Is obesity an inflammatory illness? Role of low-grade inflammation and macrophage infiltration in human white adipose tissue. BJOG 113:1141-1147.
2. Dalmas, E., C. Rouault, M. Abdennour, C. Rovere, S. Rizkalla, A. Bar-Hen, J.-L. Nahon, J.-L. Bouillot, M. Guerre-Millo, K. Clément, and C. Poitou. 2011. Variations in circulating inflammatory factors are related to changes in calorie and carbohydrate intakes early in the course of surgery-induced weight reduction. Am. J. Clin. Nutr. 94:450-458.
3. Lumeng, C. N., and A. R. Saltiel. 2011. Inflammatory links between obesity and metabolic disease. J. Clin. Invest. 121:2111-2117.
4. Mathieu, P., I. Lemieux, and J.-P. Després. 2010. Obesity, inflammation, and cardiovascular risk. Clin. Pharmacol. Ther. 87:407-416.
5. Ghanim, H., A. Aljada, D. Hofmeyer, T. Syed, P. Mohanty, and P. Dandona. 2004. Circulating mononuclear cells in the obese are in a proinflammatory state. Circulation 110:1564-1571.
6. Rizvi, A. A. 2009. Cytokine biomarkers, endothelial inflammation, and atherosclerosis in the metabolic syndrome: emerging concepts. Am. J. Med. Sci. 338:310-318.
7. Dalmas, E., K. Clément, and M. Guerre-Millo. 2011. Defining macrophage phenotype and function in adipose tissue. Trends Immunol. 32:307-314.
8. Ziegler-Heitbrock, H. W. 2000. Definition of human blood monocytes. J. Leukoc. Biol. 67:603-606.
9. Auffray, C., D. K. Fogg, E. Narni-Mancinelli, B. Senechal, C. Trouillet, N. Saederup, J. Leemput, K. Bigot, L. Campisi, M. Abitbol, et al. 2009. CX3CR1+ CD115+ CD135+ common macrophage/DC precursors and the role of CX3CR1 in their response to inflammation. J. Exp. Med. 206:595-606.
10. Geissmann, F., M. G. Manz, S. Jung, M. H. Sieweke, M. Merad, and K. Ley. 2010. Development of monocytes, macrophages, and dendritic cells. Science 327:656-661.
11. Ziegler-Heitbrock, L., P. Ancuta, S. Crowe, M. Dalod, V. Grau, D. N. Hart, P. J. M. Leenen, Y.-J. Liu, G. MacPherson, G. J. Randolph, et al. 2010. Nomenclature of monocytes and dendritic cells in blood. Blood 116:e74-e80.
12. Poitou, C., E. Dalmas, M. Renovato, V. Benhamo, F. Hajduch, M. Abdennour, J.-F. Kahn, N. Veyrie, S. Rizkalla, W.-H. Fridman, et al. 2011. CD14dimCD16+ and CD14+CD16+ monocytes in obesity and during weight loss: relationships with fat mass and subclinical atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 31:2322-2330.
13. Ziegler-Heitbrock, L. 2007. The CD14+ CD16+ blood monocytes: their role in infection and inflammation. J. Leukoc. Biol. 81:584-592.
14. Zhao, C., H. Zhang, W.-C. Wong, X. Sem, H. Han, S.-M. Ong, Y.-C. Tan, W.-H. Yeap, C.-S. Gan, K.-Q. Ng, et al. 2009. Identification of novel functional differences in monocyte subsets using proteomic and transcriptomic methods. J. Proteome Res. 8:4028-4038.
15. Cros, J., N. Cagnard, K. Woollard, N. Patey, S.-Y. Zhang, B. Senechal, A. Puel, S. K. Biswas, D. Moshous, C. Picard, et al. 2010. Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. Immunity 33:375-386.
16. Wong, K. L., J. J.-Y. Tai, W.-C. Wong, H. Han, X. Sem, W.-H. Yeap, P. Kourilsky, and S.-C. Wong. 2011. Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets. Blood 118:e16-e31.
17. Zawada, A. M., K. S. Rogacev, B. Rotter, P. Winter, R.-R. Marell, D. Fliser, and G. H. Heine. 2011. SuperSAGE evidence for CD14++CD16+ monocytes as a third monocyte subset. Blood 118:e50-e61.
18. Repnik, U., M. Knezevic, and M. Jeras. 2003. Simple and cost-effective isolation of monocytes from buffy coats. J. Immunol. Methods 278:283-292.
19. Krinninger, P., R. Ensenauer, K. Ehlers, K. Rauh, J. Stoll, S. Krauss-Etschmann, H. Hauner, and H. Laumen. 2014. Peripheral monocytes of obese women display increased chemokine receptor expression and migration capacity. J. Clin. Endocrinol. Metab. 99:2500-2509.
20. Shah, R., C. C. Hinkle, J. F. Ferguson, N. N. Mehta, M. Li, L. Qu, Y. Lu, M. E. Putt, R. S. Ahima, and M. P. Reilly. 2011. Fractalkine is a novel human adipochemokine associated with type 2 diabetes. Diabetes 60:1512-1518.
21. Polyák, A., S. Ferenczi, A. Dénes, Z. Winkler, R. Kriszt, B. Pintér-Kübler, and K. J. Kovács. 2014. The fractalkine/Cx3CR1 system is implicated in the development of metabolic visceral adipose tissue inflammation in obesity. Brain Behav. Immun. 38:25-35.
22. Combadière, C., S. Potteaux, J.-L. Gao, B. Esposito, S. Casanova, E. J. Lee, P. Debré, A. Tedgui, P. M. Murphy, and Z. Mallat. 2003. Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. Circulation 107:1009-1016.
23. Lesnik, P., C. A. Haskell, and I. F. Charo. 2003. Decreased atherosclerosis in CX3CR1-/-mice reveals a role for fractalkine in atherogenesis. J. Clin. Invest. 111:333-340.
24. Damås, J. K., A. Boullier, T. Waehre, C. Smith, W. J. Sandberg, S. Green, P. Aukrust, and O. Quehenberger. 2005. Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, is elevated in coronary artery disease and is reduced during statin therapy. Arterioscler. Thromb. Vasc. Biol. 25:2567-2572.
25. Apostolakis, S., E. Krambovitis, Z. Vlata, G. E. Kochiadakis, S. Baritaki, and D. A. Spandidos. 2007. CX3CR1 receptor is up-regulated in monocytes of coronary artery diseased patients: impact of pre-inflammatory stimuli and reninangiotensin system modulators. Thromb. Res. 121:387-395.
26. Ikejima, H., T. Imanishi, H. Tsujioka, M. Kashiwagi, A. Kuroi, T. Tanimoto, H. Kitabata, K. Ishibashi, K. Komukai, T. Takeshita, and T. Akasaka. 2010. Upregulation of fractalkine and its receptor, CX3CR1, is associated with coronary plaque rupture in patients with unstable angina pectoris. Circ. J. 74:337-345.
27. Fong, A. M., L. A. Robinson, D. A. Steeber, T. F. Tedder, O. Yoshie, T. Imai, and D. D. Patel. 1998. Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J. Exp. Med. 188:1413-1419.
28. Lucas, A. D., C. Bursill, T. J. Guzik, J. Sadowski, K. M. Channon, and D. R. Greaves. 2003. Smooth muscle cells in human atherosclerotic plaques express the fractalkine receptor CX3CR1 and undergo chemotaxis to the CX3C chemokine fractalkine (CX3CL1). Circulation 108:2498-2504.
29. Tacke, F., D. Alvarez, T. J. Kaplan, C. Jakubzick, R. Spanbroek, J. Llodra, A. Garin, J. Liu, M. Mack, N. Van Rooijen, et al. 2007. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J. Clin. Invest. 117:185-194.
30. Combadière, C., S. Potteaux, M. Rodero, T. Simon, A. Pezard, B. Esposito, R. Merval, A. Proudfoot, A. Tedgui, and Z. Mallat. 2008. Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C (hi) and Ly6C (lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice. Circulation 117:1649-1657.
31. Braunersreuther, V., S. Steffens, C. Arnaud, G. Pelli, F. Burger, A. Proudfoot, and F. Mach. 2008. A novel RANTES antagonist prevents progression of established atherosclerotic lesions in mice. Arterioscler. Thromb. Vasc. Biol. 28:1090-1096.
32. Jones, K. L., J. J. Maguire, and A. P. Davenport. 2011. Chemokine receptor CCR5: from AIDS to atherosclerosis. Br. J. Pharmacol. 162:1453-1469.
33. Keophiphath, M., C. Rouault, A. Divoux, K. Clément, and D. Lacasa. 2010. CCL5 promotes macrophage recruitment and survival in human adipose tissue. Arterioscler. Thromb. Vasc. Biol. 30:39-45.
34. Bursill, C. A., M. L. Castro, D. T. Beattie, S. Nakhla, E. Van Der Vorst, A. K. Heather, P. J. Barter, and K.-A. Rye. 2010. High-density lipoproteins suppress chemokines and chemokine receptors in vitro and in vivo. Arterioscler. Thromb. Vasc. Biol. 30:1773-1778.
35. Lin, H., E. Lee, K. Hestir, C. Leo, M. Huang, E. Bosch, R. Halenbeck, G. Wu, A. Zhou, D. Behrens, et al. 2008. Discovery of a cytokine and its receptor by functional screening of the extracellular proteome. Science 320:807-811.
36. Wei, S., S. Nandi, V. Chitu, Y.-G. Yeung, W. Yu, M. Huang, L. T. Williams, H. Lin, and E. R. Stanley. 2010. Functional overlap but differential expression of CSF-1 and IL-34 in their CSF-1 receptor-mediated regulation of myeloid cells. J. Leukoc. Biol. 88:495-505.
37. Levine, J. A., M. D. Jensen, N. L. Eberhardt, and T. O'Brien. 1998. Adipocyte macrophage colony-stimulating factor is a mediator of adipose tissue growth. J. Clin. Invest. 101:1557-1564.
38. Harman-Boehm, I., M. Blüher, H. Redel, N. Sion-Vardy, S. Ovadia, E. Avinoach, I. Shai, N. Klöting, M. Stumvoll, N. Bashan, and A. Rudich. 2007. Macrophage infiltration into omental versus subcutaneous fat across different populations: effect of regional adiposity and the comorbidities of obesity. J. Clin. Endocrinol. Metab. 92:2240-2247.
39. Medzhitov, R. 2001. Toll-like receptors and innate immunity. Nat. Rev. Immunol. 1:135-145.
40. Shi, H., M. V. Kokoeva, K. Inouye, I. Tzameli, H. Yin, and J. S. Flier. 2006. TLR4 links innate immunity and fatty acid-induced insulin resistance. J. Clin. Invest. 116:3015-3025.
41. Fresno, M., R. Alvarez, and N. Cuesta. 2011. Toll-like receptors, inflammation, metabolism and obesity. Arch. Physiol. Biochem. 117:151-164.